Does Teva's Return To Profitability And Branded-Drug Shift Reshape The Bull Case For TEVA? [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
Beyond the headline numbers, Teva's progress in shifting toward higher-margin branded drugs and advancing its late-stage pipeline is reshaping the company's business mix. We'll now examine how Teva's improving profitability and expanding innovative portfolio could influence its investment narrative for investors. This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality For Teva, I think the investment case now hinges on believing the “pivot to growth” story is real: that the company can steadily replace a slower, pressured generics base with a more profitable, branded and biosimilar portfolio while keeping its sizeable debt under control. The latest full-year 2025 results, showing a shift from loss to US$1.41 billion in net income on US$17.26 billion of sales, back that narrative and explain why the stock has pushed to a 52-week high, even if consensus price targets are now only modestly above the market price. In the near
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis [Yahoo! Finance]Yahoo! Finance
- Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TEVA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WMarketBeat
- Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Barclays PLC from $35.00 to $38.00. They now have an "overweight" rating on the stock.MarketBeat
- Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $36.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
TEVA
Earnings
- 1/28/26 - Beat
TEVA
Sec Filings
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- TEVA's page on the SEC website